Art. -Nr.: HY-32735

Triptolide

(Synonyms: PG490)

74 Cited Publications

Kundenbewertung

Based on 74 publication(s) in Google Scholar

Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 38748-32-2
Formel: C₂₀H₂₄O₆
Molecular Weight:360.40

Speicherung:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Triptolide Chemical Structure

CAS. Nr.: 38748-32-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (74)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

HSP90

MDM-2/p53

47-73 nM (IC₅₀)

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.022 μM Compound: 1	Cytotoxicity against human 786-O cells after 72 hrs by MTT assay Cytotoxicity against human 786-O cells after 72 hrs by MTT assay	[PMID: 19637874]
A2780	IC₅₀	1.827 μM Compound: TN	Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]
A549	IC₅₀	0.0013 μg/mL Compound: 1	Cytotoxicity against human A549 lung tumor cells Cytotoxicity against human A549 lung tumor cells	[PMID: 16455242]
A549	IC₅₀	1.3 ng/mL Compound: 1a, triptolide	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 18321701]
A549	IC₅₀	0.059 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19637874]
A549	IC₅₀	0.019 μM Compound: 1	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21470864]
A549	IC₅₀	14 nM Compound: 19	Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay	[PMID: 23895492]
A549	IC₅₀	23 nM Compound: 19	Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA	[PMID: 23895492]
A549	IC₅₀	0.0175 μM Compound: Triptolide	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
A549	IC₅₀	0.03 μM Compound: TPE	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 28814374]
B16-F10	IC₅₀	0.005 μM Compound: 1	Antiproliferative activity against human B16-F10 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human B16-F10 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
Bel-7402	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19637874]
BGC-823	IC₅₀	0.002 μM Compound: 1	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
DU-145	IC₅₀	0.024 μM Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 19637874]
HaCaT	IC₅₀	0.027 μM Compound: TPL	Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
HCT-116	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19637874]
HCT-116	IC₅₀	4.7 nM Compound: 2	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability Cytotoxicity against human HCT116 cells assessed as decrease in cell viability	[PMID: 31121546]
HCT-116	IC₅₀	0.003 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
HCT-116	IC₅₀	0.046 μM Compound: TPL	Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
HCT-15	IC₅₀	0.029 μM Compound: 1	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 19637874]
HeLa	IC₅₀	0.047 μM Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19637874]
HeLa	IC₅₀	87 nM Compound: 2	Cytotoxicity against human HeLa cells assessed as decrease in cell viability Cytotoxicity against human HeLa cells assessed as decrease in cell viability	[PMID: 31121546]
HeLa	IC₅₀	0.043 μM Compound: TP	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
Hepatocyte	IC₅₀	37.7 nM Compound: TP	Cytotoxicity against primary hepatocytes (unknown origin) after 48 hrs by XTT assay Cytotoxicity against primary hepatocytes (unknown origin) after 48 hrs by XTT assay	[PMID: 30613335]
HepG2	IC₅₀	43.3 nM Compound: TP	Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay	[PMID: 30613335]
HepG2	IC₅₀	0.014 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
HepG2	IC₅₀	0.033 μM Compound: TP	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HepG2	IC₅₀	0.468 μM Compound: Triptolide	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay	[PMID: 35476958]
HT-29	IC₅₀	0.0001 μg/mL Compound: 1	Cytotoxicity against human HT29 colon tumor cells Cytotoxicity against human HT29 colon tumor cells	[PMID: 16455242]
HT-29	IC₅₀	0.1 ng/mL Compound: 1	Cytotoxicity against human HT29 colon tumor cells Cytotoxicity against human HT29 colon tumor cells	[PMID: 16455242]
HT-29	IC₅₀	0.1 ng/mL Compound: 1a, triptolide	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 18321701]
HT-29	IC₅₀	0.0021 μM Compound: 1	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21470864]
HT-29	IC₅₀	0.047 μM Compound: TPL	Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
Huh-7	IC₅₀	74.63 nM Compound: TN	Cytotoxicity against human Huh-7 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]
HUVEC	IC₅₀	0.044 μM Compound: TPL	Cytotoxicity against HUVEC incubated for 72 hrs by MTT assay Cytotoxicity against HUVEC incubated for 72 hrs by MTT assay	[PMID: 35617856]
Jurkat	IC₅₀	140 nM Compound: 2	Cytotoxicity against human Jurkat cells assessed as decrease in cell viability Cytotoxicity against human Jurkat cells assessed as decrease in cell viability	[PMID: 31121546]
K562	IC₅₀	0.05 μM Compound: 1	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19637874]
KB	IC₅₀	0.043 μM Compound: 1	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19637874]
KB	ED₅₀	2.6 μg/mL Compound: Triptolide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 7130986]
KBM5	IC₅₀	10.3 nM Compound: 1	Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay	[PMID: 20149665]
KBM5	IC₅₀	8.3 nM Compound: 1	Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay	[PMID: 20149665]
L02	IC₅₀	0.021 μM Compound: TP	Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
L02	IC₅₀	0.016 μM Compound: TPL	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
LNCaP	IC₅₀	9.7 nM Compound: 1	Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35247754]
MCF7	IC₅₀	0.019 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19637874]
MCF7	IC₅₀	0.022 μM Compound: TP	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
MDA-MB-231	IC₅₀	0.024 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19637874]
MDA-MB-231	IC₅₀	0.051 μM Compound: TPL	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
MDA-MB-468	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human MDA-MB-468 cells by SRB assay Cytotoxicity against human MDA-MB-468 cells by SRB assay	[PMID: 19637874]
MDCK	IC₅₀	1200 nM Compound: 2	Cytotoxicity against MDCK cells assessed as decrease in cell viability Cytotoxicity against MDCK cells assessed as decrease in cell viability	[PMID: 31121546]
MEF	IC₅₀	9200 nM Compound: 1	Cytotoxicity against MEF after 72 hrs by MTS assay Cytotoxicity against MEF after 72 hrs by MTS assay	[PMID: 20149665]
MKN-28	IC₅₀	0.2 μM Compound: 1	Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay	[PMID: 19637874]
MOLT-4	IC₅₀	0.017 μM Compound: 1	Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 19637874]
MV4-11	IC₅₀	12.03 nM Compound: TP; 1	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 36115206]
NCI-H1299	IC₅₀	0.049 μM Compound: TP	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
NCI-H1650	IC₅₀	0.015 μM Compound: 1	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
NCI-H1975	IC₅₀	0.019 μM Compound: TP	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
NCI-H1975	IC₅₀	0.002 μM Compound: TPL	Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
NCI-H460	IC₅₀	0.014 μM Compound: TPL	Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
NIH3T3	IC₅₀	50 nM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells assessed as decrease in cell viability Cytotoxicity against mouse NIH/3T3 cells assessed as decrease in cell viability	[PMID: 31121546]
PANC-1	IC₅₀	0.2 μM Compound: 8; TPL	Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay	[PMID: 33289552]
PANC-1	IC₅₀	0.056 μM Compound: TP	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
PC-3	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 19637874]
PC-3	IC₅₀	0.043 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19637874]
PC-3	IC₅₀	0.02 μM Compound: 1	Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay	[PMID: 20833543]
PC-3	IC₅₀	20 nM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 24378709]
PC-3	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	[PMID: 25467158]
PC-3	IC₅₀	0.0183 μM Compound: Triptolide	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
PC-3	IC₅₀	0.021 μM Compound: TP	Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
PC-3	IC₅₀	20.3 nM Compound: 1	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35247754]
RAW264.7	IC₅₀	0.014 μM Compound: 1	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 32028140]
RAW264.7	IC₅₀	0.023 μM Compound: 1	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 32028140]
SGC-7901	IC₅₀	0.015 μM Compound: 1	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 19637874]
SJRH30	IC₅₀	0.014 μM Compound: 1	Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay	[PMID: 19637874]
SK-OV-3	IC₅₀	0.009 μM Compound: 1	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 19637874]
SK-OV-3	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 19637874]
SK-OV-3	IC₅₀	0.006 μM Compound: 1	Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay	[PMID: 20833543]
SK-OV-3	IC₅₀	6 nM Compound: 1	Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 24378709]
SK-OV-3	IC₅₀	0.0072 μM Compound: Triptolide	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	802.6 nM Compound: TN	Cytotoxicity against human SK-OV-3 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SK-OV-3 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]
SMMC-7721	IC₅₀	0.018 μM Compound: 1	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 19637874]
SW 1116	IC₅₀	0.052 μM Compound: 1	Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay	[PMID: 19637874]
SW480	IC₅₀	50 nM Compound: 77	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 33445154]
SW-620	IC₅₀	0.163 μM Compound: TPL	Cytotoxicity against human SW-620 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SW-620 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
THP-1	IC₅₀	7.04 nM Compound: TP; 1	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay	[PMID: 36115206]
U-251	IC₅₀	0.049 μM Compound: 1	Cytotoxicity against human U251 cells after 72 hrs by MTT assay Cytotoxicity against human U251 cells after 72 hrs by MTT assay	[PMID: 19637874]
U-251	IC₅₀	0.033 μM Compound: 1	Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	[PMID: 25467158]

In Vitro

Triptolide induces apoptosis in cultured and primary Chronic Lymphocytic Leukemia (CLL) B-cells. Treatment of CD19⁺ B cells with Triptolide, induces a dose-dependent increase in apoptosis in cultured and primary CLL cells. Triptolide is selectively toxic to both high risk (n=5) and low risk CLL (n=12) B cells (10 to 50 nM range) while largely sparing normal B-cells (n=5). Consistent with the inhibition of heat-shock induced HSP transcription, treatment with Triptolide attenuates heat-shock induced expression of HSPs^[1]. Triptolide is a natural product derived from the Chinese plant Tripterygium wilfordii, is reported to exhibit antitumor effects in a broad range of cancers. Triptolide inhibits MDM2 expression in a dose-dependent manner, even at low concentrations spanning 20-100 nM in acute lymphoblastic leukemia (ALL) cells. Triptolide exhibits strongly cytotoxic activity in all 8 cell lines having native MDM2 overexpression, with IC₅₀ values range from 47 to 73 nM. Triptolide exhibits much less cytotoxic effect on EU-4 cells that express very low level of MDM2, while it effectively kill these cells when MDM2 is stably transfected (IC₅₀ values: 725 nM vs. 88 nM)^[2]. Differentiated PC12 cells are incubated with different concentrations of Triptolide (0.01, 0.1, and 1 nM) in the presence of 10 μM Aβ_25-35 for 24 hours and MTT assay is used to detect the effect of Triptolide. The results show that Aβ_25-35 can decrease the cell viability and when treated with Triptolide the viability of differentiated PC12 cells is significantly increased. The results indicate that Triptolide can alleviate cellular damage caused by Aβ_25-35, which means that Triptolide has a neuroprotective effect^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

The Triptolide (TP) plasma concentrations are declined rapidly in mice after receive an intravenous dose. After 2h of injection, the Triptolide concentrations are dropped below the lower limit of quantification for all three groups. A comparison of the parameters is made between the control and the treated groups to assess the effect of P-gp inhibition on the Triptolide exposure and elimination. Treatment with the mdr1a-siRNA can significantly enhance the Triptolide plasma exposure, with the C_max increases from 413±74 to 510±94 ng/mL (P<0.05) and the AUC from 103.5±9.6 to 154.3±30.2 ng h/mL (P<0.05). In the concomitant group with Tariquidar, the significantly increased AUC is also noted, from 103.5±9.6 of the control to 145.9±24.6 ng h/mL of the Triptolide+Tariquidar group (P<0.05). Accordingly, the total body clearance of Triptolide in mice is remarkably decreased, from 9564±1024.2 mL/min/kg of the control to 6576.4±1438.5 (P<0.05) and 5755.4±1200.1 mL/min/kg (P<0.05) for Triptolide+Tariquidar and Triptolide+mdr1a-siRNA groups, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 38748-32-2
Appearance Solid
Molecular Weight 360.40
Formel C₂₀H₂₄O₆
Color White to off-white
SMILES

C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
Synonyms

PG490
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (74)

All Cell Imaging/StainingCell Proliferation/Viability AssayWBFlow Cytometry

Sort by:

Journal Impact Factor

Science

Microglia replacement halts the progression of microgliopathy in mice and humans. [Abstract]

2025 Jul 10;389(6756):eadr1015. PMID: 40638739
Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Cell Metab

Portal vein-enriched metabolites as intermediate regulators of the gut microbiome in insulin resistance. [Abstract]

2025 Aug 29:S1550-4131(25)00361-4. PMID: 40914155
Blood

The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. [Abstract]

2020 Jul 23;136(4):501-515. PMID: 32291445

Triptolide purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]

Representative immunofluorescence image of p-NF-κB (red: Alexa Fluor 594) in BMDMs cultured with Triptolide (20 nM), TMAO or TMAO+Triptolide for 24 hrs.

Triptolide purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]

Immunoblotting analysis of NLRP3 in BMDMs treated with Triptolide (20 nM), TMAO or TMAO+Triptolide for 24 hrs.
Nucleic Acids Res

TriTag: an integrative tool to correlate chromatin dynamics and gene expression in living cells. [Abstract]

2020 Dec 16;48(22):e127. PMID: 33104788

Triptolide purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2020 Dec 16;48(22):e127. [Abstract]

Live-cell imaging snapshots of a cell illustrating chromatin dynamics and transcription activation with the addition of Triptolide (30 μM) under the stress condition (42℃, 0.03% CO₂).
ACS Meas Sci Au

2025 Nov 27.
Adv Sci (Weinh)

Mitochondrial CISD1 Modulates Microglial Metabolic Reprogramming to Drive Stress Susceptibility in Mice. [Abstract]

2025 Nov 11:e08957. PMID: 41215712
Cell Death Dis

HHIPL2 positively governs Hedgehog signaling to accelerate non-small cell lung cancer progression via enhancing HNRNPC-mediated HNF1A mRNA stabilization. [Abstract]

2025 Dec 18. PMID: 41413056
Cell Death Dis

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. [Abstract]

2019 Aug 9;10(8):602. PMID: 31399555
J Immunother Cancer

PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression. [Abstract]

2023 Nov;11(11):e007627. PMID: 37914384

Triptolide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2023 Nov;11(11):e007627. [Abstract]

Western blotting to detect the protein expression of nuclear-p65 and PD-L1 after addition of inhibitor Triptolide to sh-PER2-CAL27#2 cells.

Triptolide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2023 Nov;11(11):e007627. [Abstract]

Flow cytometry to detect alterations in positive PD-L1 expression on the cell membrane surface after addition of inhibitor Triptolide to sh-PER2-CAL27#2 cells.
J Neuroinflammation

Integration and functionality of human iPSC-derived microglia in a chimeric mouse retinal model. [Abstract]

2025 Feb 27;22(1):53. PMID: 40016767
Phytomedicine

Tripterygium glycosides reverse cisplatin resistance in epithelial ovarian cancer by activating ferroptosis via two different pathways. [Abstract]

2026 Mar:152:157865. PMID: 41619560
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Clin Cancer Res

CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma. [Abstract]

2024 Sep 13;30(18):4179-4189. PMID: 39052240
Clin Cancer Res

Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. [Abstract]

2020 Apr 15;26(8):2011-2021. PMID: 31937620

Triptolide purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. [Abstract]

BON-1 (closed circles) and QGP1 (open circles) cells were exposed to increasing concentrations of Triptolide (0.001-10 μM) for 5 days. The proportion of viable cells is shown on the y-axis, with the dosage on the x-axis. The IC50 values (μM) are denoted.
NPJ Precis Oncol

DDX41 facilitates PD-L1-mediated immune escape in OSCC via the phase separation and activation STING pathway. [Abstract]

2026 Feb 11;10(1):126. PMID: 41673322
Proc Natl Acad Sci U S A

Activation of P53 pathway contributes to Xenopus hybrid inviability. [Abstract]

2023 May 23;120(21):e2303698120. PMID: 37186864
Proc Natl Acad Sci U S A

Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. [Abstract]

2020 May 5;117(18):9964-9972. PMID: 32312817
Phytother Res

Triptolide enhances lipolysis of adipocytes by enhancing ATGL transcription via upregulation of p53. [Abstract]

2020 Dec;34(12):3298-3310. PMID: 32614500
Free Radic Biol Med

Triptolide alleviates acute lung injury by reducing mitochondrial dysfunction mediated ferroptosis through the STAT3/p53 pathway. [Abstract]

2025 Mar 16:230:79-94. PMID: 39914683
Free Radic Biol Med

New mechanism of nephrotoxicity of triptolide: Oxidative stress promotes cGAS-STING signaling pathway. [Abstract]

2022 Aug 1:188:26-34. PMID: 35697291
Br J Cancer

Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]

2023 Mar;128(7):1344-1359. PMID: 36717670
Cell Rep

2025 Dec 29;45(1).
Cell Rep

Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. [Abstract]

2018 Sep 4;24(10):2553-2560.e5. PMID: 30184490
Cancer Cell Int

Natural compound triptolide induces caspase-3/GSDME-mediated pyroptosis by promoting ROS accumulation in small cell lung cancer. [Abstract]

2025 Nov 28;25(1):426. PMID: 41316249
Drug Des Devel Ther

Downregulation of miR-200a Protects Mouse Leydig Cells Against Triptolide by Triggering Autophagy. [Abstract]

2020 Nov 10;14:4845-4854. PMID: 33204070
Drug Des Devel Ther

Triptolide Inhibits the Proliferation of HaCaT Cells Induced by IL22 via Upregulating miR-181b-5p. [Abstract]

2020 Jul 22;14:2927-2935. PMID: 32801634
ACS Biomater Sci Eng

Light-Based 3D Bioprinting of Testicular Organoid as an In Vitro Model for Reproductive Toxicity Assessment. [Abstract]

2025 Jul 14;11(7):4357-4367. PMID: 40570049
Int Immunopharmacol

Enhanced BEST2 expression in keratinocytes alleviates psoriatic inflammation. [Abstract]

2025 Jun 17:161:115077. PMID: 40532325
Int Immunopharmacol

Triptolide alleviates allergic airway inflammation by inhibiting group 2 innate lymphoid cell function. [Abstract]

2025 Jan 6:147:113989. PMID: 39765003
Int Immunopharmacol

A synergistic effect of triptolide and curcumin on rheumatoid arthritis by improving cell proliferation and inducing cell apoptosis via inhibition of the IL-17/NF-κB signaling pathway. [Abstract]

2024 Sep 2;142(Pt A):112953. PMID: 39226828
Int J Mol Sci

S100A4 Promotes BCG-Induced Pyroptosis of Macrophages by Activating the NF-κB/NLRP3 Inflammasome Signaling Pathway. [Abstract]

2023 Aug 11;24(16):12709. PMID: 37628889
Int Immunopharmacol

Triptolide decreases rheumatoid arthritis fibroblast-like synoviocyte proliferation, invasion, inflammation and presents a therapeutic effect in collagen-induced arthritis rats via inactivating lncRNA RP11-83J16.1 mediated URI1 and β-catenin signaling. [Abstract]

2021 Oct:99:108010. PMID: 34358861
Int J Mol Sci

Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. [Abstract]

2016 Dec 19;17(12). pii: E2139. PMID: 27999372

Triptolide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139. [Abstract]

To explore the cellular mechanisms for the suppression of CNE cells by TPL and IR, the expression of p65, phosph-p65, Bcl-2, and Bax in CNE cells are examined by Western blot, with β-actin as protein loading control. Western blot assay for Bax, Bcl-2, phosph-p65, and p65 expression in vitro with combined treatment with TPL and IR.
Front Pharmacol

Triptolide Induces Leydig Cell Apoptosis by Disrupting Mitochondrial Dynamics in Rats. [Abstract]

2021 Mar 9;12:616803. PMID: 33767625
Expert Opin Ther Targets

Therapeutic impact of thymoquninone to alleviate ischemic brain injury via Nrf2/HO-1 pathway. [Abstract]

2021 Jul;25(7):597-612. PMID: 34236288
Mol Med Rep

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. [Abstract]

2023 Jan;27(1):17. PMID: 36453238
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Cancers (Basel)

Triptolide Triggers Protective Autophagy via ROS Induction in NSCLC: Therapeutic Synergy with Autophagy Inhibition. [Abstract]

2026 Mar 11;18(6):902. PMID: 41899507
Cancers (Basel)

Triptolide Reduces Neoplastic Progression in Hepatocellular Carcinoma by Downregulating the Lipid Lipase Signaling Pathway. [Abstract]

2024 Jan 27;16(3):550. PMID: 38339301
J Cell Mol Med

Hic-5 deficiency protects cerulein-induced chronic pancreatitis via down-regulation of the NF-κB (p65)/IL-6 signalling pathway. [Abstract]

2020 Jan;24(2):1488-1503. PMID: 31797546
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
Antiviral Res

Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity. [Abstract]

2026 Jun:250:106417. PMID: 42025967
J Biol Chem

A new technique for genome-wide mapping of nucleotide excision repair without immunopurification of damaged DNA. [Abstract]

2022 Mar 23;298(5):101863. PMID: 35339490
J Biol Chem

An integrated PKD1-dependent signaling network amplifies IRE1 prosurvival signaling. [Abstract]

2019 Jul 19;294(29):11119-11130. PMID: 31167779
Viruses

TGF-β from the Porcine Intestinal Cell Line IPEC-J2 Induced by Porcine Circovirus 2 Increases the Frequency of Treg Cells via the Activation of ERK (in CD4+ T Cells) and NF-κB (in IPEC-J2). [Abstract]

2022 Nov 8;14(11):2466. PMID: 36366564
J Biochem Mol Toxicol

Triptolide Attenuates Traumatic Heterotopic Ossification via Modulation of Inflammatory and Differentiation Pathways: Implications for Biochemical Toxicology. [Abstract]

2025 Sep;39(9):e70482. PMID: 40891665
Toxicol Appl Pharmacol

Triptolide impairs glycolysis by suppressing GATA4/Sp1/PFKP signaling axis in mouse Sertoli cells. [Abstract]

2021 Aug 15:425:115606. PMID: 34087332
Immun Inflamm Dis

Quantitative proteomic analysis of circulating exosomes reveals the mechanism by which Triptolide protects against collagen-induced arthritis. [Abstract]

2024 Jun;12(6):e1322. PMID: 38888462
Transl Lung Cancer Res

Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer. [Abstract]

2022 May;11(5):802-816. PMID: 35693277
Neuroscience

Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation. [Abstract]

2022 Jan 1:480:56-64. PMID: 34774714
Brain Res

Unraveling the therapeutic potential of triptolide in glioma: Orchestrating apoptosis and immune landscape remodeling. [Abstract]

2026 Jan 1:1870:150039. PMID: 41205732
BMC Gastroenterol

Triptolide attenuates irritable bowel syndrome via inhibiting ODC1. [Abstract]

2023 Jun 12;23(1):202. PMID: 37308808
Toxicol Lett

Multi-omics analysis reveals the mechanism of indirect hepatotoxicity of triptolide upon LPS stimulation. [Abstract]

2025 Dec 9:415:111802. PMID: 41381020
Am J Cancer Res

m6A methyltransferase METTL3 promotes oral squamous cell carcinoma progression through enhancement of IGF2BP2-mediated SLC7A11 mRNA stability. [Abstract]

2021 Nov 15;11(11):5282-5298. PMID: 34873461
IBRO Neurosci Rep

Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury. [Abstract]

2024 May 23:17:13-21. PMID: 38872838
PLoS One

Suggested Involvement of PP1/PP2A Activity and De Novo Gene Expression in Anhydrobiotic Survival in a Tardigrade, Hypsibius dujardini, by Chemical Genetic Approach. [Abstract]

2015 Dec 21;10(12):e0144803. PMID: 26690982
Biochemistry

Discovery of a Potent Tat-Binding Antiretroviral Compound Using a Two-Step Screening Approach. [Abstract]

2025 Dec 16;64(24):4692-4705. PMID: 41312763
Cytotechnology

Triptolide attenuates LPS-induced chondrocyte inflammation by inhibiting inflammasome activation via the Wnt/β-catenin and NF-κB signaling pathways. [Abstract]

2025 Feb;77(1):13. PMID: 39665044
Neurosci Lett

Inhibiting RGS1 attenuates secondary inflammation response and tissue degradation via the TLR/TRIF/NF-κB pathway in macrophage post spinal cord injury. [Abstract]

2022 Jan 18:768:136374. PMID: 34852285
Biol Pharm Bull

Triptolide Suppresses Growth of Breast Cancer by Targeting HMGB1 in Vitro and in Vivo. [Abstract]

2019 Jun 1;42(6):892-899. PMID: 30956264
bioRxiv

2026 May 25.
Cell Investig

2026 May 14;2(2):100076.
bioRxiv

Histone H4 acetyl-methyllysine marks accessible chromatin that resists compaction. [Abstract]

2026 Apr 21:2026.04.17.718779. PMID: 42079196
bioRxiv

2026 Mar 26.
bioRxiv

2025 Sep 21.
bioRxiv

A single cluster of RNA Polymerase II molecules is stably associated with active genes. [Abstract]

2025 Feb 11:2025.02.10.637507. PMID: 39990393
bioRxiv

2024 Jul 25.
bioRxiv

2024 July 27.
The Hong Kong Polytechnic University

2023 Aug.
University of Rijeka

2023.
Research Square Print

2022 May.
Research Square Preprint

2021 Mar.
Research Square Preprint

2020 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (69.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7747 mL

13.8735 mL

27.7469 mL

5 mM

0.5549 mL

2.7747 mL

5.5494 mL

10 mM

0.2775 mL

1.3873 mL

2.7747 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.17 mg/mL (3.25 mM); Clear solution

This protocol yields a clear solution of ≥ 1.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.17 mg/mL (3.25 mM); Clear solution

This protocol yields a clear solution of ≥ 1.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[3]

The viability of differentiated PC12 cells treated with different concentrations of Triptolide. After differentiated PC12 cells are cultured on 96-well plates with RPMI 1640 medium for stabilization, differentiated PC12 cells are incubated with different concentrations of Triptolide (0.01, 0.1, and 1 nM) for 24 hours. The concentrations in this study are chosen. Then cell viability is determined by the MTT assay. Each condition and experiment is repeated three times^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Mice^[4]
Male BALB/C mice (weight, 18-22 g) are used. For Triptolide (TP) plasma kinetic study and toxicological evaluation, mice are divided into four groups (n=5 each) to collect blood and tissue samples: (1) normal+saline group; (2) 1.0 mg/kg Triptolide+15 nmol negative control (NC) siRNA-siRNA group; (3) 1.0 mg/kg Triptolide+15 nmol mdr1a-siRNA group; (4) 1.0 mg/kg Triptolide+10 mg/kg Tariquidar group. In order to avoid the complication caused by drug absorption or possible intestinal first-pass effect, Triptolide and the inhibitor are intravenously administrated to mice. The siRNA group is intravenously injected with NC-siRNA or mdr1a-siRNA 2 days before Triptolide dose. For Triptolide+Tariquidar group, the mice are received an intravenous Tariquidar dose 20 min prior to the Triptolide injection. Blood samples are collected at 2, 5, 10, 15, 30, 60 and 120 min after Triptolide dosing. To assess the liver exposure of Triptolide, liver tissue samples are collected from another set of mice at 5, 30, 60 and 120 min after dosing. Three Triptolide groups are design for this experiment, including Triptolide+NC-siRNA group, Triptolide+mdr1a-siRNA group and Triptolide+Tariquidar group. The liver tissue samples are weighed and then homogenized in 10 volume (w:v) of ice-cold saline. The concentrations of Triptolide in plasma and liver tissue are measured by a validated LC-MS/MS method.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Oct 13;6(31):31767-79. [Content Brief]

[2]. Huang M, et al. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013 Feb;12(2):184-94. [Content Brief]

[3]. Xu P, et al. Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta25-35 via the Autophagy Pathway. PLoS One. 2015 Nov 10;10(11):e0142719. [Content Brief]

[4]. Kong LL, et al. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep. 2015 Jul 2;5:11747. [Content Brief]

[5]. Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139. [Content Brief]

[6]. Cai J, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40(1):190. Published 2021 Jun 9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7747 mL	13.8735 mL	27.7469 mL	69.3674 mL
	5 mM	0.5549 mL	2.7747 mL	5.5494 mL	13.8735 mL
	10 mM	0.2775 mL	1.3873 mL	2.7747 mL	6.9367 mL
	15 mM	0.1850 mL	0.9249 mL	1.8498 mL	4.6245 mL
	20 mM	0.1387 mL	0.6937 mL	1.3873 mL	3.4684 mL
	25 mM	0.1110 mL	0.5549 mL	1.1099 mL	2.7747 mL
	30 mM	0.0925 mL	0.4624 mL	0.9249 mL	2.3122 mL
	40 mM	0.0694 mL	0.3468 mL	0.6937 mL	1.7342 mL
	50 mM	0.0555 mL	0.2775 mL	0.5549 mL	1.3873 mL
	60 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1561 mL

Keywords

Triptolide

74 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Triptolide

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

NMPA-Approved Drug Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Aging Natural Product Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Pesticide Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Environmental Pollutant Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Triptolide